Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates

(NASDAQ:ALGS), SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced a progress update for the Phase 2 B-SUPREME study of pevifoscorvir sodium in subjects with chronic hepatitis B virus […]

InnovAge to Announce Fiscal Second Quarter 2026 Financial Results and Host Conference Call Tuesday, February 3, 2026

(NASDAQ:INNV), DENVER, Jan. 21, 2026 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced it will release its 2026 fiscal second quarter financial results on Tuesday,

Manulife to Release Fourth Quarter and Full Year 2025 Results

C$ unless otherwise stated TSX/NYSE/PSE: MFC SEHK: 945 Manulife Financial Corporation will release its fourth quarter and full year 2025 financial results after markets close on Wednesday, February 11, 2026, which will be made available at manulife.com/en/investors/results-and-reports. A live webcast and conference call are scheduled for Thursday, February 12, 2026, at 8:00 a.m. (ET) where

Super League Announces 1-for-12 Reverse Split

(NASDAQ:SLE), SANTA MONICA, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) — Super League (Nasdaq: SLE) (the “Company”), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, announced today a reverse stock split of its issued and outstanding shares of common stock, par value $0.001

Legend Biotech to Present CARVYKTI(R) Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

(NASDAQ:LEGN), Six poster presentations highlight CARVYKTI(R) efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will present six poster presentations featuring data on CARVYKTI(R) (ciltacabtagene

Amanda Demanda Injury Lawyers Appoints Miriam Fresco Agrait, Esq. as Managing Partner

MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) — Amanda Demanda Injury Lawyers announced that Miriam Fresco Agrait, Esq. has joined the firm as Managing Partner, marking a significant milestone in the firm's continued growth and expansion. A Board Certified Civil Trial Lawyer, Fresco Agrait brings decades of leadership, courtroom experience, and community-driven advocacy to the role.

Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)

(NASDAQ:ECOR), ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society have launched a new research initiative to explore the extent to which gammaCore(TM) Sapphire, electroCore's non-invasive vagus nerve stimulator (nVNS), can be used as

Twin Disc Announces Details of Fiscal 2026 Second Quarter Earnings Release, Webcast, and Conference Call

(NASDAQ:TWIN), MILWAUKEE, Jan. 21, 2026 (GLOBE NEWSWIRE) — Twin Disc, Inc. (NASDAQ: TWIN), today announced that it will release its fiscal 2026 second-quarter results at approximately 8:00 am Eastern on February 4, 2026, and host a webcast and conference call to discuss those results at 9:00 am Eastern. Following their prepared remarks, the Company will

WSP Announces Details for the Release of Its 2025 Fourth Quarter and Year-End Results

(TSX:WSP), MONTREAL, Jan. 21, 2026 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”), one of the world's leading professional services firms, will release its 2025 fourth quarter and year-end results on February 25, 2026, after market close. A conference call and webcast will be held on February 26, 2026, at 8:00

LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

(NasdaqGM:LBRX), NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment Dr. Minako Pazdera as General Counsel. Dr. Pazdera joins LB Pharmaceuticals with more than 25 years of

Scroll to Top